MDCO stock: buy or sell?
January 3rd, 2020
The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.
Should I buy MDCO stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
These 2 buy setups are elegible for The Medicines stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is The Medicines stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for MDCO stock for the last month.
MDCO stock analysis
The Medicines touched new all time highs again on January, setting highs to $84.98. Shares closed at $84.90 and stayed steady -0.07%.
The Medicines closed on January at $84.90 after reaching a new all time high ($84.98) even it couldn't close with gains and stayed constant a tight -0.07%. Since August when MDCO stock price broke up the SMA100d line, it gained $52.07 (158.60%).
Shares of The Medicines closed this week at $84.90 after marking a new all time high ($84.98) and stayed constant a neutral 0.14%. Late November 2019 MDCO rocketed an extraordinary 18.59% in just one week. For 5 weeks in a row, price soared and marked a profit of 1.02%. By mid November 2019 MDCO plummed a bloodcurdling -5.83% in just one week.
The Medicines stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, MDCO might consolidate in a flat-base, waiting to break out over or down under . Since SMA20d and SMA40w crossed up late May 2019, MDCO price climbed $51.91 per share (157.35%). Since early April 2019 when MDCO stock price broke up the SMA40w line, it gained $56.95 (203.76%).
MDCO stock price history
MDCO stock went public on August 8th, 2000 with a price of $17.941. Since then, MDCO stock surged a 373.20%, with an average of 19.60% per year. If you had invested $1,000 in MDCO stock in 2000, it would worth $3,732.00 today.
1: Adjusted price after possible price splits or reverse-splits.
MDCO stock historical price chart
MDCO stock reached all-time highs on January with a price of $84.98.
MDCO stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not detected any price prediction for The Medicines stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, The Medicines reported its latest financial data, posting a great growth for the Earnings per Share (EPS). Experts expected $-0.58 per share, but The Medicines posted $-0.67.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, The Medicines annual sales plunged a chilling -86.30% to $6.14 million dollars from $44.79 marked in 2017. Similarly, its profit margin (compared to revenues) collapsed to -2,006.45%, that is $-123.16 million.
|2013||$688 M||-||$16 M2.3%||-|
|2014||$724 M||5.31%||$-32.21 M-4.4%||-307.67%|
|2015||$309 M||-57.34%||$-352.76 M-114.2%||995.18%|
|2016||$168 M||-45.69%||$-119.12 M-71.0%||-66.23%|
|2017||$45 M||-73.31%||$-708.37 M-1581.6%||494.68%|
|2018||$6.14 M||-86.30%||$-123.16 M-2006.5%||-82.61%|
Quarterly financial resultsThe Medicines posted $0.00 M in sales for 2018-Q4, a -100.00% decline compared to previous quarter. Reported quarter earnings marked $-42.47 M with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was 1,685.88%. When comparing revenues to same quarter last year, The Medicines sales marked a scary correction and plummed a -100.00%.
|2017-Q2||$18.74 M||-||$-397.27 M-2119.9%||-|
|2017-Q3||$16.87 M||-9.97%||$-30.18 M-178.9%||-92.40%|
|2017-Q4||$8.60 M||-49.05%||$-178.26 M-2074.0%||490.75%|
|2018-Q1||$7.77 M||-9.59%||$29.15 M375.1%||-116.35%|
|2018-Q2||$1.67 M||-78.55%||$-54.20 M-3251.2%||-285.93%|
|2018-Q3||$-3.30 M||-297.96%||$-55.63 M1685.9%||2.65%|
The Medicines ownershipWhen you are planning to buy a stock, it's worth to review its ownership structure.
The Medicines shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, January 3rd, 2020|
|Day range||$84.88 - $84.98|
|Average true range||$0.17|
|50d mov avg||$71.86|
|100d mov avg||$59.07|
|200d mov avg||$46.19|
The Medicines performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For The Medicines, the benchmark is made against .